Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Funder
- European Commission · Horizon Europe
- Award amount
- €6,000,000 – €8,000,000
- Deadline
- February 17, 2027
- Eligible countries
- European Union, United Kingdom, Norway, Iceland, Switzerland, Israel, Global
Summary
Forthcoming EU call topic HORIZON-HLTH-2027-02-TOOL-01-two-stage · HORIZON Research and Innovation Actions. Part of call HORIZON-HLTH-2027-02-two-stage: Cluster 1 - Health (Two stage - 2027). Opens 2026-10-29; next deadline 2027-02-17 (first stage). Topic page: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-02-TOOL-01-two-stage
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and tackle the unmet clinical needs of non-communicable chronic diseases. - Clinicians and healthcare professionals use clinically validated predictive biomarkers for implementing more effective clinical research and personalised medicine with better health outcomes in chronic non-communicable diseases. - Key stakeholders have access to trustworthy Artificial Intelligence (AI) tools to guide the development of multimodal predictive biomarkers of higher accuracy and clinical value when compared to the established practice. - The citizens benefit of better health outcomes thanks to improved clinical guidelines and the implementation of effective biomarker-guided clinical research and personalised healthcare.
Scope: Biomarkers[1] are invaluable tools for improving patient outcomes, guiding treatment decisions, accelerating personalised medicine, more effective clinical research and the development of better medicines. However, despite the scientific discoveries of many clinically relevant biomarkers, estimated on the…
Summary as listed by the funder. Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement →What European Union reviewers look for
- Most Horizon Europe calls score three criteria (the ERC uses excellence alone). Excellence: clarity and ambition of the objectives, and the soundness of the methodology.
- Impact: credible pathways to the expected outcomes, and measures to communicate and exploit results.
- Quality and efficiency of implementation: the work plan, resources and the consortium's capacity.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free